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Figure 2. Average age for patient groups admitted 
before and after 2012, p<0.05 (N= 619 vs 687, 
respectively).
Figure 3. Average PSA levels in patients 
admitted before and after 2012, p>0.05 NS 
(N= 619 vs 687, respectively). 
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Figure 4. Patients sub-grouped into gleason
score (GG) shows an increase in clinically 
significant prostate cancer GG ≥ 2 in the 
post-2012 group compared to pre-2012, 
with 430 patients vs 351, respectively (Chi-
sqaured test p < .05). 
Figure 5. A significant relationship is 
depicted between cancer risk and time period 
when patients are admitted. There is an 
increase in patients with intermediate and 
very high risk cancer in the post-2012 group, 
and less in the very low and low risk group 
compared to the pre-2012 group (Chi-squared 
test p < 0.01).
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The purpose of our study is to assess the effects of the USPSTF grade D 
recommendation for PSA based screening on new PCa diagnoses within a large-
community based private practice setting. 
According to the National Cancer Institute, prostate cancer is the most common 
non-cutaneous malignancy diagnosed in American men.  Approximately 164,690 
men will be diagnosed and 29,430 men will die from prostate cancer (PCa) in 
2018 [1]. Prostate cancer specific antigen (PSA) is a serine-protease enzyme 
secreted by both normal and neoplastic prostatic tissue [2]. PSA is secreted into 
the glandular ducts of the prostate, and is elevated in the serum with prostatic 
inflammatory and neoplastic disease, thus serving as a marker for prostatic 
metastasis [2]. 
Since the introduction of prostate specific antigen (PSA) the diagnosis incidence 
of prostate cancer has increased drastically. Over the same time period, prostate 
cancer mortality has decreased almost 40% [1,3,4]. The United States Preventive 
Services Task Force (USPSTF), however, recommended against prostate cancer 
screening in men older than age 75 and noted insufficient evidence to determine 
the balance of benefits and harms of screening for prostate cancer in men 
younger than age 75, grade D (Fig. 1) [5]. As a result of the USPSTF 
recommendations, there has been a decrease in prostate cancer screening using 
prostate needle biopsies, digital rectal exams and PSA levels [6,7].
We completed a retrospective chart review of men with an elevated PSA seen in 
our clinic between May 2009–May 2015 who had undergone a prostate biopsy 
and were diagnosed with PCa. Further stratification of patients by age and risk 
category was investigated (Very low risk PCa was diagnosed according to 
Epstein criteria, while low, intermediate and high risk were classified according 
to D’Amico assessment). A student’s T-test was used to compare means between 
groups, and a chi-squared test of independence was performed to examine the 
relation between date of screening and study variables. 
Figure 1. The USPSTF recommendation grade definitions [8].
We observed that following the 2012 USPSTF recommendations, there was a 
significant increase in patients with clinically significant prostate cancer GG ≥ 2, 
with the majority being 55-65 years of age. In addition we observed a decrease 
in the diagnosis of very low and low risk PCa with an increased incidence of 
intermediate and high risk PCa. 
p<0.05 NS
The USPSTF has issued recommendation against the screening of prostate cancer 
using PSA levels for men younger than 75 years of age, noting insufficient 
evidence that benefits outweigh the harm associated with the screening test. 
Since then, practices and clinics have reported reduced screening measures with 
an associated increase in prostate cancer diagnoses following the 
recommendation [7].
We investigated the impact of the USPSTF recommendation on the new 
diagnoses of PCa in a community based private clinical practice. We report a 
shift in the PCa characteristics of admitted patients with elevated serum PSA 
levels. Overall, patients admitted were younger after the recommendations. 
Specifically more patients below the age of 70 years were admitted due to 
elevated PSA levels after 2012, and less were admitted over the age of 70. In 
addition, patients presented with a significantly more developed prostatic tumour
(GG ≥ 2), and more patients were seen with intermediate and high risk cancer 
upon examination as compared to low and very risk cancer.
These observations suggest a possible role for the recommendations in the 
increasing trend of more advanced prostatic neoplasia seen on initial 
examination. This could be due to the decrease of early screening measures with 
less biopsies, digital rectal exams as well as PSA level monitoring performed by 
primary care physicians. However, this merits further investigation into the role 
of the recommendations in higher risk prostate cancer diagnoses. 
Figure 6. Age-stratification shows an 
increase in the majority of admitted patients 
from being  ≥70 years of age (51%) to being 
55-69 years (55%) after the year 2012 (Chi-
squared test p < .01). 
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